Mechanisms of resistance to JAK2 inhibitors in myeloproliferative neoplasms
SC Meyer - Hematology/Oncology Clinics, 2017 - hemonc.theclinics.com
Myeloproliferative neoplasms (MPNs) are chronic leukemias occurring at an annual
incidence of 0.5 to 1.0 per 100,000. 1 They are hematopoietic stem cell disorders leading to
excessive proliferation of mature myeloid cells. The 3 main MPN clinical phenotypes include
essential thrombocythemia (ET) with marked thrombocytosis, polycythemia vera (PV) with
erythrocytosis often along with neutrophilia and thrombocytosis, and myelofibrosis (MF) with
expansion of megakaryocytes, progressive bone marrow fibrosis, and extramedullary …
incidence of 0.5 to 1.0 per 100,000. 1 They are hematopoietic stem cell disorders leading to
excessive proliferation of mature myeloid cells. The 3 main MPN clinical phenotypes include
essential thrombocythemia (ET) with marked thrombocytosis, polycythemia vera (PV) with
erythrocytosis often along with neutrophilia and thrombocytosis, and myelofibrosis (MF) with
expansion of megakaryocytes, progressive bone marrow fibrosis, and extramedullary …